Literature DB >> 15451479

The clinical and biological overlap between Nijmegen Breakage Syndrome and Fanconi anemia.

A R Gennery1, M A Slatter, A Bhattacharya, D Barge, S Haigh, M O'Driscoll, R Coleman, M Abinun, T J Flood, A J Cant, P A Jeggo.   

Abstract

Fanconi anemia (FA), an autosomal recessive chromosomal instability syndrome, is characterized clinically by developmental abnormalities, growth retardation, progressive bone marrow failure, pancytopenia, and pronounced cancer predisposition. Nijmegen Breakage Syndrome (NBS) is a related disorder that shares overlapping clinical features, principally, developmental delay, microcephaly, and cancer predisposition. The diagnosis has relied on chromosomal instability following exposure to DNA cross-linking agents in FA and to ionizing radiation (IR) in NBS. We describe two patients who clinically had FA, but showed sensitivity to both DNA cross-linking agents and ionizing radiation, and who were found to have a rare mutation in the NBS gene. The importance of genetic diagnosis with respect to treatment and prognosis is discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15451479     DOI: 10.1016/j.clim.2004.03.024

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  21 in total

1.  Nbs1 is required for ATR-dependent phosphorylation events.

Authors:  Tom Stiff; Caroline Reis; Gemma K Alderton; Lisa Woodbine; Mark O'Driscoll; Penny A Jeggo
Journal:  EMBO J       Date:  2004-12-16       Impact factor: 11.598

2.  Radiosensitive severe combined immunodeficiency disease.

Authors:  Christopher C Dvorak; Morton J Cowan
Journal:  Immunol Allergy Clin North Am       Date:  2010-02       Impact factor: 3.479

3.  Nijmegen breakage syndrome (NBS) with neurological abnormalities and without chromosomal instability.

Authors:  E Seemanová; K Sperling; H Neitzel; R Varon; J Hadac; O Butova; E Schröck; P Seeman; M Digweed
Journal:  J Med Genet       Date:  2005-07-20       Impact factor: 6.318

4.  BRCA2 is required for neurogenesis and suppression of medulloblastoma.

Authors:  Pierre-Olivier Frappart; Youngsoo Lee; Jayne Lamont; Peter J McKinnon
Journal:  EMBO J       Date:  2007-05-03       Impact factor: 11.598

5.  Diagnosis of Fanconi anemia in patients with bone marrow failure.

Authors:  Fernando O Pinto; Thierry Leblanc; Delphine Chamousset; Gwenaelle Le Roux; Benoit Brethon; Bruno Cassinat; Jérôme Larghero; Jean-Pierre de Villartay; Dominique Stoppa-Lyonnet; André Baruchel; Gérard Socié; Eliane Gluckman; Jean Soulier
Journal:  Haematologica       Date:  2009-03-10       Impact factor: 9.941

6.  Identification and characterization of mutations in FANCL gene: a second case of Fanconi anemia belonging to FA-L complementation group.

Authors:  Abdullah Mahmood Ali; Michelle Kirby; Michael Jansen; Francis P Lach; Jennifer Schulte; Thiyam Ramsing Singh; Sat D Batish; Arleen D Auerbach; David A Williams; Amom Ruhikanta Meetei
Journal:  Hum Mutat       Date:  2009-07       Impact factor: 4.878

Review 7.  Phenotypes and genotypes of the chromosomal instability syndromes.

Authors:  Zhan-He Wu
Journal:  Transl Pediatr       Date:  2016-04

8.  Fanconi DNA repair pathway is required for survival and long-term maintenance of neural progenitors.

Authors:  Karine Sii-Felice; Olivier Etienne; Françoise Hoffschir; Céline Mathieu; Lydia Riou; Vilma Barroca; Céline Haton; Fré Arwert; Pierre Fouchet; François D Boussin; Marc-André Mouthon
Journal:  EMBO J       Date:  2008-01-31       Impact factor: 11.598

9.  ATR-dependent phosphorylation and activation of ATM in response to UV treatment or replication fork stalling.

Authors:  Thomas Stiff; Sarah A Walker; Karen Cerosaletti; Aaron A Goodarzi; Eva Petermann; Pat Concannon; Mark O'Driscoll; Penny A Jeggo
Journal:  EMBO J       Date:  2006-11-23       Impact factor: 11.598

10.  Cutaneous sarcoid-like granulomas in a child known with nijmegen breakage syndrome.

Authors:  Rachisan Andreea Liana; Gheban Dan; Miu Nicolae
Journal:  Iran J Pediatr       Date:  2013-02       Impact factor: 0.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.